ArcticZymes Technologies octroie une licence exclusive à une nouvelle technologie d’assemblage d’ADN
Tromsø,Norway , 08[th]December 2022 -ArcticZymes Technologies ASA (OSE: AZT) exclusively licenses novel DNA assembly technology from UiTThe Arctic University ofNorway ArcticZymes Technologies (AZT) has signed an exclusive licensing agreement with UiTThe Arctic University ofNorway (UiT) for a novel DNA assembly technology. The technology was developed by researchers at UiT and is based on unique heat -labile enzymes identified by marine bioprospecting inthe Arctic . The patent -pending technology comprises novel enzymes with tailor-made characteristics for controlled and efficient assembly of multiple DNA fragments. DNA assembly is a work-horse technology serving a growing demand for gene- and vector- constructs, enabling innovation in areas such as synthetic biology and in the development of therapeutics. Synthetic biology is a growing multidisciplinary field seeking to take advantage of synthetic genes and genomes, generating new and improved biological systems to solve challenges in medicine, manufacturing, and applied markets. The global synthetic biology market was estimated at$9.6 billion in 2021 and projected to grow at a compound annual growth rate (CAGR) of 26%. By acquiring this technology, the Company will expand its offering towards new and existing customers in both the molecular tools and biomanufacturing businesses.ArcticZymes Technologies ASA , CEO,Jethro Holter said: "DNA assembly technologies are being utilised by biomanufacturers and service providers, or offered as molecular tools for integration into application workflows. The technology licensed by AZT will circumvent limitations in current technologies. We are delighted to enter into a further agreement with UiT. It builds on our long-term partnership which has been successful in commercialising multiple discoveries." UiTThe Arctic University ofNorway , Head of Department, Department of chemistry,Annette Bayer said: "This technology is a great achievement for UiT, our researchers, collaborators, and theNorwegian Research Council , and can enable technology advances in important areas in the future. We are happy to have entered an agreement with an experienced partner likeArcticZymes to make the technology available". For more information, please contact: CEO,Jethro Holter Tel: +47 46 85 91 46 CFO, Børge Sørvoll Tel: +47 95 29 01 87 ir@arcticzymes.com AboutArcticZymes Technologies ASA ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research,In Vitro Diagnostics (IVD) and biomanufacturing. Listed on theOslo Stock Exchange since 2005 originally under the [Biotec] ticker, asBiotec Pharmacon . The company rebranded asArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø,Norway , at the SIVA Innovation Centre.ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents. For more information, please visit the website: www.arcticzymes.com. UiTThe Arctic University ofNorway The Arctic University ofNorway is the northernmost university of the world. Its location on the edge ofthe Arctic implies a mission.The Arctic is of increasing global importance. Climate change, the exploitation of Arctic resources and environmental threats are topics of great public concern, and which the University of Tromsø takes special interest in. UiT's key research focuses on the polar environment, climate research, indigenous people, peace and conflict transformation, telemedicine, medical biology, space physics, fishery science, marine bioprospecting, linguistics and computational chemistry. For more information, please visit the website: https://en.uit.no/startsida
Cliquez ici pour plus d’informations
© Oslo Bors ASA, source